PERLAPINE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C19H21N3
Molecular Weight	291.3901
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CN1CCN(CC1)C2=NC3=C(CC4=C2C=CC=C4)C=CC=C3

InChI

InChIKey=PWRPUAKXMQAFCJ-UHFFFAOYSA-N

InChI=1S/C19H21N3/c1-21-10-12-22(13-11-21)19-17-8-4-2-6-15(17)14-16-7-3-5-9-18(16)20-19/h2-9H,10-14H2,1H3

HIDE SMILES / InChI

Molecular Formula	C19H21N3
Molecular Weight	291.3901
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.ncbi.nlm.nih.gov/pubmed/9577836
Curator's Comment: Description is created based on several sources, including http://www.ncbi.nlm.nih.gov/pubmed/4359662 and http://www.ncbi.nlm.nih.gov/pubmed/4695567

Perlapine ‎is a sedative and hypnotic drug.The drug brand named Hypnodin contains generic salt-Perlapine and is manufactured by Takeda Pharmaceutical. Perlapine is a potent H1R inverse agonist. It showed robust sedative effects clinically. Perlapine belongs to antipsychotic drugs which elicit little or no Parkinsonism, it binds more loosely than dopamine to D2 receptors.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Dopamine D2 receptor 297 Target ID: CHEMBL339 Sources: http://www.ncbi.nlm.nih.gov/pubmed/11462978	Inhibitor 8297	2.7 µM [IC50]
Histamine H1 receptor 315 Target ID: CHEMBL231 Sources: http://www.ncbi.nlm.nih.gov/pubmed/17403993	Inverse Agonist 80	9.7 null [pIC50]
Dopamine D2 receptor 297 Target ID: CHEMBL217 Sources: http://www.ncbi.nlm.nih.gov/pubmed/9577836	Binding Agent 1064	60.0 nM [Kd]
Dopamine D3 receptor 91 Target ID: CHEMBL234 Sources: http://www.ncbi.nlm.nih.gov/pubmed/9577836	Binding Agent 1064	100.0 nM [Kd]
Dopamine D4 receptor 71 Target ID: CHEMBL219 Sources: http://www.ncbi.nlm.nih.gov/pubmed/9577836	Binding Agent 1064	30.0 nM [Kd]
Serotonin 2a (5-HT2a) receptor 231 Target ID: CHEMBL224 Sources: http://www.ncbi.nlm.nih.gov/pubmed/9577836	Binding Agent 1064	13.0 nM [Kd]
Melatonin receptor 1A 6 Target ID: CHEMBL1945 Sources: http://www.genome.jp/dbget-bin/www_bget?D01438	Agonist 2678
Melatonin receptor 1B 6 Target ID: CHEMBL1946 Sources: http://www.genome.jp/dbget-bin/www_bget?D01438	Agonist 2678

Conditions

Condition	Modality	Targets	Highest Phase	Product
Sleep disorder 20 Sources: http://www.ncbi.nlm.nih.gov/pubmed/4359662	Primary		Approved 8429	Hypnodin Approved Use Hypnotic and sedative

PubMed

Title	Date	PubMed
The effects of perlapine on sleep.	1973 Aug 22	4359662
Anti-dopaminergic and anti-muscarinic effects of dibenzodiazepines: relationship to drug induced Parkinsonism.	1976	7753
Perlapine and dopamine metabolism: prediction of antipsychotic efficacy.	1977 Jan 7	12986
Perlapine: relationship between stimulation of prolactin secretion and antipsychotic activity.	1977 Oct 20	412213

Patents

Sample Use Guides

In Vivo Use Guide

10 - 20 mg of perlapine nightly to improve sleep

Route of Administration: Oral

In Vitro Use Guide

Perlapine inhibited spiropiperidone binding at dopamine receptor D2 of rat with IC50 2.7uM

Substance Class	Chemical Created by `admin` on `Fri Dec 15 14:58:58 GMT 2023` Edited by `admin` on `Fri Dec 15 14:58:58 GMT 2023`
Record UNII	4N8UJJ27IM
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

PERLAPINE

Official Name

English

perlapine [INN]

Common Name

English

PERLAPINE [MI]

Common Name

English

AW 14'2333

Code

English

PERLAPINE [MART.]

Common Name

English

NSC-291840

Code

English

AW 142333

Code

English

Perlapine [WHO-DD]

Common Name

English

AW-142333

Code

English

PERLAPINE [JAN]

Common Name

English

11H-DIBENZ(B,E)AZEPINE, 6-(4-METHYL-1-PIPERAZINYL)-

Systematic Name

English

PERLAPINE [USAN]

Common Name

English

HYPNODIN

Brand Name

English

Classification Tree Code System Code

NCI_THESAURUS

C29756